The purchase price, and that is confidential and was negotiated for all in all , 300 million doses, is somewhat lower than the $19.50 per picture the United States agreed to buy a first shipment of 100 million doses of the identical vaccine, in line with what Reuters reported in November.
The EU file dated Nov. eighteen was circulated internally after the EU announced the supply offer of its with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is anticipated to determine on Monday on acceptance for the Pfizer vaccine following the shot was authorised in several countries, including Britain and also the United States.
On Thursday Belgian declare secretary for the spending budget Eva De Bleeker released on Twitter a dinner table with prices Belgium will pay pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the article shortly after posting.
In this table the Pfizer vaccine was suggested as costing Belgium 12 euros ($14.6) per dose, leading many to believe that has been the total price agreed by way of the EU.
Various other vaccines in the table were additionally shown with prices lower than rates disclosed by EU solutions.
“There is for sure a full fee along with a cost upon delivery,” an EU official required in talks with vaccine makers told Reuters when directed to clarify the difference between the EU and Belgian prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament previous week. In this public hearing, De Beeker said Belgium’s budgeted costs were still partial.
Under EU advance purchase deals for COVID 19 vaccines, the bloc agrees initial payments with businesses to secure doses before they’re approved. After approvals, EU governments are able to pay the rest to purchase reserved doses.
The EU hasn’t revealed the upfront transaction agreed with Pfizer.
But, it said in October that it paid about one billion euros inside downpayments to AstraZeneca, Sanofi and Johnson and Johnson for their shots, with a further 1.45 billion euros budgeted for upfront payments to Pfizer BioNTech, Moderna and Curevac.
It has since agreed supply deals with all six organizations and is negotiating a seventh arrangement with Novavax.